Mysler, E, Ignatenko, S, Gordienko, A, Cort s-Hern ndez, J, Agmon-Levin, N, Narongroeknawin, P, Romanowska-Prochnicka, K, Shen, N, Cifersk , H, Kodera, M, Wei, JCC, Leszczynski, P, Lan, JL, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Dai, L, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, Magallares, BP, Sengupta, T, Sips, C, Lau, C, Avrameas, A, Oliver, SJ. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

Zhang, YL, Tedeschi, S, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, J, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, D az, C, McCarthy, G, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Tarancon, LC, Stamp, L, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, FitzGerald, J, Dalbeth, N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

Lopez-Gutierrez, F, Loricera, J, Hormigos, C, Nu ez, DF, Rodriguez-Laguna, M, Albarado, PM, G mez, MLI, Corominas, H, Silva-D az, M, Arribas, GG, Garcia-Aparicio, A, Urgelles, JF, Casafont-Sole, I, Calabuig, PM, Castaneda, E, Merino, C, Zas, R, Molina-Collada, J, Melero-Gonzalez, RB, Galindez-Agirregoikoa, E, Hern ndez-Mart n, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, V zquez, NM, Gallego-Flores, A, Ra a, NC, Veroz, R, Andres, M, Casta eda, S, Blanco-Alonso, R. Effectiveness of Rituximab in IgG4 Related Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

Guerrero, MR, Moriano, C, Santos, CS, Herranz, LS, Garcia, JJ, Barranco, IC, Alvarez, ED. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).